Vitiligo happens when your immune system mistakenly attacks and destroys melanocytes, the cells responsible for producing skin pigment. This isn’t a single event but a chain reaction involving genetic vulnerability, a buildup of cellular stress, and an immune response that targets your own pigment cells. About 0.67% of adults worldwide have vitiligo, roughly 37 million people, and the condition can appear at any age.
What Happens Inside the Skin
Melanocytes sit at the base of your epidermis and produce melanin, the pigment that gives skin its color. In vitiligo, these cells come under attack from multiple directions. The process typically starts with oxidative stress, a buildup of harmful molecules called reactive oxygen species (ROS) that damage the internal machinery of melanocytes. People with vitiligo have measurably low levels of catalase, an enzyme that normally breaks down hydrogen peroxide in the skin. Without enough catalase, hydrogen peroxide accumulates to levels that have been directly detected in affected skin using specialized imaging.
This chemical imbalance triggers a cascade of problems inside the melanocyte. Mitochondria, the cell’s energy producers, begin leaking electrons that generate even more ROS. The cell’s protein-folding system becomes overwhelmed, producing misfolded proteins that trigger an emergency response. When that emergency response runs too long, it becomes lethal to the cell. At the same time, oxidative stress weakens the physical bonds between melanocytes and the surrounding skin cells (keratinocytes), causing pigment cells to detach from their normal position.
The stressed melanocytes don’t just quietly die. They release internal proteins to their surface that essentially flag them as targets for the immune system. This is where vitiligo shifts from a cellular stress problem to a full autoimmune attack.
The Immune System’s Role
The core of vitiligo is autoimmune destruction. A specific type of immune cell, the CD8+ T cell, is the primary killer. These cells are designed to destroy virus-infected or abnormal cells, but in vitiligo they become “autoreactive,” meaning they recognize melanocyte proteins as threats and attack healthy pigment cells.
The signaling chain works through a protein called interferon-gamma (IFNγ). When released near the skin, IFNγ triggers surrounding cells to produce chemical signals called CXCL9 and CXCL10. CXCL9 recruits large numbers of killer T cells into the skin, while CXCL10 guides them precisely to the border between the dermis and epidermis, right where melanocytes live. Blocking IFNγ in research settings significantly reduces disease severity, confirming its central role.
What makes vitiligo persistent is a subset of these killer T cells called resident memory T cells. These cells take up permanent residence in depigmented skin patches. When melanocytes try to regrow from hair follicles (a natural replenishment process), these memory cells detect them and restart the attack. This is why vitiligo patches tend to reappear in the same locations even after successful treatment.
Genetics Set the Stage
Vitiligo runs in families, though it doesn’t follow a simple inheritance pattern. Genome-wide studies have identified at least 17 genetic regions that increase susceptibility. Most of these genes control immune function: they regulate T cell activation, inflammatory signaling, and how the immune system distinguishes self from non-self. Vitiligo patients and their family members carry a higher risk of other autoimmune diseases, including thyroid disease (affecting up to 19.4% of vitiligo patients), type 1 diabetes, pernicious anemia, and Addison’s disease.
One gene stands out as unique among the 17. TYR encodes tyrosinase, the key enzyme melanocytes use to produce melanin. A common variant of this gene increases vitiligo risk by about 2.5 times in people who carry two copies. Interestingly, this same variant appears to interact with a specific immune gene (HLA-A*0201) to compound the risk, illustrating how vitiligo requires both immune and melanocyte-specific genetic factors to develop.
Environmental and Chemical Triggers
Genetics load the gun, but something in the environment often pulls the trigger. In some cases, the trigger is identifiable. Certain phenol-based chemicals, particularly 4-tertiary butyl phenol and monobenzyl ether of hydroquinone, can directly initiate vitiligo. These compounds are structurally similar to tyrosine, the amino acid melanocytes use to build melanin. When melanocytes absorb these chemicals, they generate ROS, overwhelm the cell’s stress responses, and set off the same autoimmune cascade seen in spontaneous vitiligo. Workers in industries that manufacture or use phenols face the highest exposure risk, and the effect is dose-dependent: more exposure means greater likelihood of developing the condition.
Physical trauma to the skin can also trigger new patches, a phenomenon called the Koebner response. Cuts, burns, sunburns, and even friction from tight clothing can cause depigmentation in people who are genetically susceptible. The common thread across all these triggers appears to be the induction of oxidative stress in melanocytes, which then exposes them to immune detection.
For most people with vitiligo, no single external trigger is ever identified. The condition is classified as idiopathic, meaning the initial stressor remains unknown even though the downstream immune destruction follows the same pathway.
Segmental vs. Non-Segmental Vitiligo
Not all vitiligo behaves the same way. Non-segmental vitiligo, the most common type, tends to appear symmetrically on both sides of the body and progresses over time. Segmental vitiligo appears on only one side, typically follows the distribution of a nerve, and usually stabilizes after an initial period of spreading.
Segmental vitiligo has a stronger connection to the nervous system. Nerve-related chemicals like neuropeptide-Y and dopamine appear to play a central role in melanocyte destruction in these cases. These substances create a two-way communication network between skin nerves, the hormonal system, and the immune system. Through their influence on local inflammation, they ultimately feed into the same immune pathway (involving CXCL9 and T cell recruitment) that drives non-segmental vitiligo. The difference is that the triggering event is neurological rather than purely immunological.
How Vitiligo Is Identified
Vitiligo patches are completely depigmented, meaning they have lost all color rather than just fading. Dermatologists typically confirm this using a Wood’s lamp, an ultraviolet light that makes depigmented skin glow bright white, distinguishing it from conditions where pigment is merely reduced. Several other conditions can mimic vitiligo’s appearance, including pityriasis alba (common in children, with lighter but not white patches), tinea versicolor (a fungal infection), and a rare type of skin lymphoma that causes pale spots. When the diagnosis is uncertain, a small skin biopsy or blood tests can rule out these alternatives.
Because vitiligo shares genetic roots with other autoimmune diseases, thyroid function testing is commonly recommended. Up to one in five vitiligo patients develops thyroid autoimmunity, making it the most frequent associated condition.